Five to ten years. That’s how long it will be before drug reimbursement in the United States becomes as stringent as in Europe, according to a range of consultants, analysts, and health policy experts with whom I’ve spoken.
This new reimbursement environment – and the expectations leading up to it – is expected to emphasize the value of “profound” innovation, at the expense of less dramatic, incremental innovation.
To read the original article: Will (Should) Incremental Biopharma Innovation Survive The Reimbursement Apocalypse? - Forbes
